Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Convertible Debt: 2019-2024

Historic Convertible Debt for Cytokinetics (CYTK) over the last 6 years, with Dec 2024 value amounting to $552.4 million.

  • Cytokinetics' Convertible Debt rose 61.30% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 61.30%. This contributed to the annual value of $552.4 million for FY2024, which is 0.62% up from last year.
  • Per Cytokinetics' latest filing, its Convertible Debt stood at $552.4 million for FY2024, which was up 0.62% from $549.0 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Convertible Debt peaked at $552.4 million during FY2024, and registered a low of $89.5 million during FY2020.
  • In the last 3 years, Cytokinetics' Convertible Debt had a median value of $549.0 million in 2023 and averaged $549.1 million.
  • Data for Cytokinetics' Convertible Debt shows a peak YoY surged of 471.70% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Cytokinetics' Convertible Debt stood at $89.5 million in 2020, then climbed by 6.67% to $95.5 million in 2021, then skyrocketed by 471.70% to $545.8 million in 2022, then rose by 0.58% to $549.0 million in 2023, then increased by 0.62% to $552.4 million in 2024.